Fredun Pharmaceuticals, a leading formulation manufacturer, reported that its net profit in the September quarter was up 90 per cent at ₹19 crore as compared to ₹10 crore in the same period last year on better demand.
Revenue was up 85 per cent at ₹266 crore (₹144 crore last year). EBITDA jumped 91 per cent to ₹43 crore (₹22 crore).
The company bought 26 per cent stake in Goodman Vetcare at a valuation of ₹300 crore in September. Goodman plans over 8 new stores and targets revenue of ₹100 crore by FY31.
In September 2026, Fredun acquired Furlicks from USV and its subsidiary Wellbeing Nutrition, marking its entry into pet wellness.
Furlicks makes easy-to-give oral strips covering skin and coat, gut health, joint care, calming, oral care and multivitamins.
The company plans to launch 16 new products over the next 6–9 months, taking the portfolio from 6 to 22 SKUs. The new launches will add formats such as cold-extruded, air-dried and freeze-dried products and functional biscuits.
Fredun launched a pet healthcare knowledge platform PAWTALKS with expert content on YouTube and Instagram.
Fredun Medhora, Managing Director, Fredun Pharmaceuticals, said the core formulations business was getting more efficient and added higher-margin while newer businesses in pet care, mobility, nutrition and dermaceuticals are now in a high-growth phase.
“These businesses carry better margins, so as they grow, they are steadily raising the quality of earnings. Fredun GX is now present in 19 states and pharmacies with distributors giving strong acceptance and repeat orders,” he said.
Pet care is one of the fastest-changing categories, as more pet parents treat their pets as family. The acquisition of stake in Goodman Vetcare and launch of PAWTALKS brings the company closer to a complete pet-wellness, he added.
“We are expanding capacity with the aim of building one of the largest manufacturing units at a single location in the country. We are also widening our product basket and strengthening the balance sheet,” he said.
Published on November 7, 2026
